FN-1501
- Generic Name
- FN-1501
- Brand Names
- Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N9O
- CAS Number
- 1429515-59-2
- Unique Ingredient Identifier
- 6MC966B505
- Background
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
- Indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
- Associated Conditions
- Transplanted Organ Rejection
- Associated Therapies
- -
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT06682169
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Leland Metheny
- Target Recruit Count
- 20
- Registration Number
- NCT06680661
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Short-term Glucocorticoid Combined with MMF for IgG4-RD
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Wen Zhang
- Target Recruit Count
- 63
- Registration Number
- NCT06663618
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 60
- Registration Number
- NCT06412497
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Target Recruit Count
- 38
- Registration Number
- NCT06375005
- Locations
- 🇨🇳
Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China
🇨🇳Huashan Hospital of Fudan University, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Treatment FOr Corticosteroid Dependent UveitiS
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 120
- Registration Number
- NCT06258915
Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients
- Conditions
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Lee's Pharmaceutical Limited
- Target Recruit Count
- 152
- Registration Number
- NCT06114953
- Locations
- 🇨🇳
Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Advancing Transplantation Outcomes in Children
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 200
- Registration Number
- NCT06055608
- Locations
- 🇺🇸
University of Alabama at Birmingham (Site # 71038), Birmingham, Alabama, United States
🇺🇸Children's Hospital of Los Angeles (Site #: 71036), Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center (Site #: 71026), Los Angeles, California, United States
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Conditions
- Acute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmHematopoietic and Lymphoid System NeoplasmMixed Phenotype Acute LeukemiaMyelodysplastic SyndromeMyeloproliferative NeoplasmNon-Hodgkin LymphomaChronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirateDrug: CyclophosphamideDrug: CyclosporineProcedure: Diagnostic ImagingProcedure: EchocardiographyDrug: Fludarabine PhosphateProcedure: Multigated Acquisition ScanDrug: Mycophenolate MofetilOther: Survey AdministrationDrug: ThiotepaRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06013423
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 190
- Registration Number
- NCT06001385
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Colorado Blood Cancer Institute at Presbyterian St. Luke's, Denver, Colorado, United States
🇺🇸City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.